- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal: Pembrolizumab related perforated appendicitis. (Pubmed Central) - Aug 3, 2024 Disease control achieved with this protocol did not differ significantly between elderly and younger patients but had acceptable tolerability, demonstrating its benefit even in elderly LA-NSCLC patients aged 75 years or above. In patients who develop acute abdominal pain with or without diarrhea during immunotherapy, urgent imaging, endoscopic and clinical evaluation should be performed, and bowel perforation, although rare, should be considered as a potential complication of any immunotherapy.
- |||||||||| Ibrance (palbociclib) / Pfizer
Journal, Metastases: Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast. (Pubmed Central) - Aug 3, 2024 This study demonstrates that the concurrent use of PPIs in mBC patients receiving palbociclib negatively affects PFS, particularly in the first-line setting. Nevertheless, further investigation is warranted to explore the impact of PPIs on cycle-dependent kinase 4/6 inhibitors.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Transplantation in Adult Patients with Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis: Yes or No? (Pubmed Central) - Aug 2, 2024 Patients with EBV infection to B cells could benefit from rituximab, whereas lethal outcomes may occur in patients with EBV infection to T cells, nature killer (NK) cells, or multilineages...For patients who achieved PR after initial treatment, HSCT was recommended. A wait-and-see strategy could be adopted for patients who achieved CR after initial treatment, but with the risk of failing to achieve a second CR.
- |||||||||| Epidaza (chidamide) / Chipscreen, AiRuiKa (camrelizumab) / HLB Bio Group, CART-30 / AbelZeta Pharma
Biomarker, Journal, Tumor microenvironment: Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma. (Pubmed Central) - Aug 2, 2024 P2 In this study, we evaluated the efficacy and safety of a triplet regimen consisting of the histone deacetylase inhibitor chidamide, decitabine and anti-PD-1 camrelizumab (CDP) in 52 patients with relapsed/refractory cHL who had previously received DP therapy (NCT04233294)...The classical CD30+ HRS-like cells interacted with the abundant immunosuppressive IL21+CD4+ T helper cells, forming a positive feedback loop that supported their survival...CDP treatment promoted the activation of diverse tumor-reactive CD8+ T cells and suppressed the proliferation of IL21+CD4+ T cells by inhibiting STAT1/3 signaling, thereby alleviating their immunosuppressive effects. These findings provide insights into the cHL microenvironment that contributes to anti-PD-1 resistance and highlight the therapeutic effectiveness of dual epi-immunotherapy in overcoming immunotherapy resistance.
- |||||||||| Tecartus (brexucabtagene autoleucel) / Gilead, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Journal: Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL. (Pubmed Central) - Aug 2, 2024 In conclusion, while InO exposure was associated with inferior survival outcomes following brexu-cel in unadjusted analyses, these associations were no longer significant in multivariate analyses, suggesting it is unlikely that InO negatively impacts brexu-cel efficacy. Our data instead imply that InO-exposed recipients of brexu-cel tend to be higher-risk patients with intrinsic adverse leukemia biology.
- |||||||||| Ocrevus (ocrelizumab) / Roche
Journal, HEOR: The Cost-Utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran. (Pubmed Central) - Aug 2, 2024 While adding ocrelizumab is not a cost-effective strategy at the threshold of one-time GDP per capita, its substantial clinical benefits should not be overlooked. Therefore, the importance of formulating healthcare policies regarding the use of high-cost medications like ocrelizumab, including budget allocation, resource distribution, and potential shifts in healthcare priorities, has become more crucial than ever.
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Retrospective data, Journal, Grant: Clinical experience of using brentuximab-vedotin as therapy in relapsed/refractory Hodgkin's lymphoma at Hospital Guillermo Grant Benavente, Concepci (Pubmed Central) - Aug 2, 2024 Therefore, the importance of formulating healthcare policies regarding the use of high-cost medications like ocrelizumab, including budget allocation, resource distribution, and potential shifts in healthcare priorities, has become more crucial than ever. brentuximab-vedotin is an outpatient medication with low toxicity that can optimize the treatment of patients with relapsed-refractory Hodgkin's lymphoma.
- |||||||||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Review, Journal: Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions. (Pubmed Central) - Aug 2, 2024 Veno-occlusive disease/sinusoidal obstruction syndrome is a potential complication of InO treatment, particularly when followed by HSCT. Herein, the authors review the historical development and current status of InO, strategies for mitigating the risk of InO-related veno-occlusive disease/sinusoidal obstruction syndrome, and future directions for InO research and clinical use.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas. (Pubmed Central) - Aug 2, 2024 Combination strategies incorporating ICIs with conventional chemotherapy or targeted agents show enhanced efficacy and are being explored extensively. In this review we discuss the most important features of the tumor microenvironment of NHLs and cHLs, address the therapeutic approaches with ICIs and try to outline future perspectives.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Association between skeletal muscle mass and treatment response in patients with diffuse large B-cell lymphoma. (Pubmed Central) - Aug 2, 2024 In addition, patients with low SMM were more likely to receive R-CHOP-like treatment (21.2% vs. 7%, p?=?0.022) and experienced more delays in administration (42.9% vs. 33.3%, p?=?0.452)...An interesting result was the interaction of low SMM with hypertension as a risk factor for not achieving CR (HR 2.7; 95% CI [1.1-6.5] p?=?0.034) or OS (HR 7.9; 95% CI [3.4-18.8] p?<?0.001). Low SMM was not a risk factor for achieving CR in patients with DLBCL and seemed to play a role in OS.
- |||||||||| Tecvayli (teclistamab-cqyv) / Genmab, J&J
Journal: Safety outcomes of teclistamab accelerated dose escalation. (Pubmed Central) - Aug 2, 2024 These findings may support outpatient administration for teclistamab. Accelerated dose escalation strategy allowed for the optimization of hospitalization and resources.
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Calquence (acalabrutinib) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy: Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Aug 2, 2024 P2, N=60, Recruiting, Trial primary completion date: Jun 2024 --> Jun 2025 Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- |||||||||| mocetinostat (MGCD0103) / Otsuka, BMS, Keytruda (pembrolizumab) / Merck (MSD), guadecitabine (SGI-110) / Otsuka
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. (clinicaltrials.gov) - Aug 2, 2024 P1, N=28, Active, not recruiting, Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025 Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- |||||||||| Kaitanni (cadonilimab) / Akesobio
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: COMPASSION-03: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma (clinicaltrials.gov) - Aug 2, 2024 P1/2, N=338, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Journal, Next-generation sequencing, PD(L)-1 Biomarker, IO biomarker, Metastases: Utility of next-generation sequencing in the diagnosis of metastatic melanoma: A case report. (Pubmed Central) - Aug 2, 2024 This case emphasizes the importance of molecular studies for definitive diagnosis in challenging clinical situations, especially when there is discordance among histopathological, immunohistochemical, and molecular studies. Integration of clinical, histopathological, and molecular features is warranted.
- |||||||||| Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date: Study of Abemaciclib in Dedifferentiated Liposarcoma (clinicaltrials.gov) - Aug 2, 2024 P2, N=33, Active, not recruiting, Trial completion date: Aug 2027 --> Feb 2027 | Trial primary completion date: Jan 2026 --> Jul 2025 Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
|